

## A Case of Metastatic Melanoma

Dr. Salvador Labrador<sup>\*1</sup>, Dr. Nerea Cortina-Garmendia<sup>2</sup>, Dr. Nicanor Valle-Garcia<sup>3</sup>

Health Center of La Barrera (Castro Urdiales, Cantabria, Spain), Public Health System in Cantabria (Servicio Cantabro de Salud).

salvadorlabrador@hotmail.com

**\*Corresponding Author:** Dr. Salvador Labrador, Health Center of La Barrera (Castro Urdiales, Cantabria, Spain), Public Health System in Cantabria (Servicio Cantabro de Salud).

An elderly female of 83 years of age was admitted to our outpatient clinic for a pigmented lesion of 5 millimeters diameter on the Left heel. On her Past medical history she was a Diabetic patient treated with oral antidiabetic medication. On examination the skin lesion was painful and friable and was treated topically. After one month the patient was referred to Hospital for Dermatology assessment. This lesion was surgically removed and Sentinel Lymph Node was Negative. Pathology examination concluded that it

was a Melanoma stage IV. Two years later pigmented nodular lesions between 2 and 5 millimeters of diameter appeared on the Left thigh compatible with melanocytic satellite nodules (Figure 1). After follow up at Hospital palliative care was recommended. Progressive evolution of skin lesions were observed with an increase of number and size of metastatic lesions (Figure 2). Ambulatory Management of these lesions became difficult due to local bleeding. (Figure 3). Unfortunately 2 years later the patient died.



Figure 1



Figure 2



**Figure 3**

### REFERENCES

1. Rigel DS. Cancer of the Skin. Elsevier-Saunders. 2 Edition. 2011.262-334.
2. Villalobos-Leon ML, Molina-Villaverde R, Lopez-Gonzalez JL, Alvarez de Mon-Soto M. Melanoma. *Medicine*. 2013; 11(26): 1597-607. (In Spanish).
3. Gershenwald JE, Ross MI. Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. *N Eng J Med* 2011; 364: 1738-45.
4. Newton-Bishop J, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, Wheelhouse C. The prevention diagnosis referral and management of Melanoma of the Skin: Concise guidelines. *Clin Med* 2007; 7 (3): 283-90.
5. Lacy KE, Karagiannis SN, Nestle FO. Advances in the treatment of Melanoma. *Clin Med* 2012; 12 (2): 168-71.
6. Cauley L, Balch CM, Ross MI, Robert C. Management of Sentinel –Node Metastasis in Melanoma. *N Eng J Med* 2018; 4: 85-8.
7. Robert C et al. Five year outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *N Eng J Med* 2019; 381: 626-36.
8. Das M. Non-radioactive imaging for SLNs detection in Melanoma. *Lancet Oncol*. 2019;
9. Schreuer M et al. Combination of Dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF –V600-mutant melanoma: an open label single arm, dual centre, phase 2 clinical trial. *Lancet Oncol*. 2017; 18 (4): 464-72.

**Citation:** Dr. Salvador Labrador, Dr. Nerea Cortina-Garmendia, Dr. Nicanor Valle-Garcia. *A Case of Metastatic Melanoma. Archives of Dermatology and Skin Care*. 2019; 2(2): 19-20.

**Copyright:** © 2019 Dr. Salvador Labrador, Dr. Nerea Cortina-Garmendia, Dr. Nicanor Valle-Garcia. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.